An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 901–1,000 of 1,001
Noor, F. (2019) · BRILL eBooks · doi:10.1163/9789004391192_026 · Cited by 7
Lipid membrane-based therapeutics and diagnostics
de Carvalho, P. M. B., Makowski, M., Domingues, M. M., Martins, I. C., & Santos, N. C. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108858 · Cited by 7
(2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721 · Cited by 7
Daele, M. V., Cooper, S. L., Pannucci, P., Wragg, E. S., March, J. E., de Jong, I. J., & Woolard, J. (2022) · JRSM Cardiovascular Disease · doi:10.1177/20480040221092893 · Cited by 7
Adegbola, P. I., Fadahunsi, O. S., Ogunjinmi, O. E., Adegbola, A. E., Ojeniyi, F. D., Adesanya, A., Olagoke, E., Adisa, A. D., Ehigie, A. F., Adetutu, A., et al. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101167 · Cited by 7
Takai, T., Jeffy, B. D., Prabhu, S., & Cohen, J. D. (2023) · Computational Toxicology · doi:10.1016/j.comtox.2023.100273 · Cited by 7
Probing Protein Surfaces: QSAR Analysis with Helix Mimetics
Azzarito, V., Rowell, P. R., Barnard, A., Edwards, T. A., Macdonald, A., Warriner, S. L., & Wilson, A. J. (2015) · ChemBioChem · doi:10.1002/cbic.201500504 · Cited by 7
Reynolds, P. S., Michael, M. J., & Spiess, B. D. (2017) · Trials · doi:10.1186/s13063-016-1755-9 · Cited by 7
Shah, F., Medvedev, A. V., Wassermann, A. M., Brodney, M. D., Zhang, L., Makarov, S. S., & Stanton, R. V. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx231 · Cited by 7
Majumder, A., Biswal, M. R., & Prakash, M. K. (2019) · ACS Omega · doi:10.1021/acsomega.8b02862 · Cited by 7
Bioinformatics, Genomics, and Proteomics Tools in Drug Design
Ataya, F. S. (2019) · Journal of Drug Research and Development · doi:10.16966/2470-1009.147 · Cited by 7
Key Aspects for Achieving Hits by Virtual Screening Studies
Federico, L. B., Barcelos, M. P., Silva, G. M., Francischini, I. A. G., Taft, C. A., & da Silva, C. H. T. D. P. (2021) · Engineering materials · doi:10.1007/978-3-030-62226-8_16 · Cited by 7
Gao, Y. J., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.025 · Cited by 7
Self-citationGrand Challenges for Predictive Modeling in Small Molecule Drug DiscoveryPreprint
Coley, C. W., Daga, P., Vivo, M. D., Jespers, W., Jogalekar, A. S., Kimura, S. R., Koenekoop, L., Märtson, A., Newhouse, T. R., Ray, S., et al. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15000615/v1 · Cited by 7
Human iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Structure–Activity Relationship Studies and Optimization of 4-Hydroxypyridones as GPR84 Agonists
Ieremias, L., Kaspersen, M. H., Manandhar, A., Schultz-Knudsen, K., Vrettou, C. I., Pokhrel, R., Heidtmann, C. V., Jenkins, L., Kanellou, C., Marsango, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01923 · Cited by 6
Al‐Odat, O. S., Nelson, E., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Desai, D. H., & Pandey, M. K. (2024) · Cancers · doi:10.3390/cancers16132381 · Cited by 6
Beckers, M., Sirockin, F., Fechner, N., & Stiefl, N. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00898 · Cited by 6
Stone, C. R., Harris, D. D., Broadwin, M., Sabe, S. A., Bellam, K. G., Kanuparthy, M., Abid, M. R., & Sellke, F. W. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.09.065 · Cited by 6
Recent update on the development of HPV16 inhibitors for cervical cancer
Shoaib, M., Tariq, A., Liu, Y., Yang, M., Qu, L., Yang, L., & Song, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104703 · Cited by 6
Almajidi, Y. Q., Faisal, R. R., Yaseen, A., & Al-hakeem, M. A. (2025) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1078 · Cited by 6
Bose, A., Anselmetti, G.-L., Degroote, M., Moll, N., Santagati, R., Streif, M., Weskamp, N., & Tkatchenko, A. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02491 · Cited by 6
Alberga, D., Nanna, V., Giovanna, M., Papadopoulos, E., Ancona, A., Lomuscio, M. C., & Mangiatordi, G. F. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00397 · Cited by 6
Koleiev, I., Stratiichuk, R., Shevchuk, N., Melnychenko, M., Nyporko, A. Y., Todoryshyn, D., Husak, V., Starosyla, S. A., Yesylevskyy, S. O., & Нафієв, А. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00819 · Cited by 6
Light, D. S., Aleo, M. D., & Kenna, J. G. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_17 · Cited by 6
Al-Amin, R. A., Johansson, L., Abdurakhmanov, E., Landegren, N., Löf, L., Arngården, L., Blokzijl, A., Svensson, R., Hammond, M., Lönn, P., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac842 · Cited by 6
Induced Pluripotent Stem Cells, a Stepping Stone to In Vitro Human Models of Hearing Loss
Alonso, M. B. D., & Petković, H. (2022) · Cells · doi:10.3390/cells11203331 · Cited by 6
Zhao, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115830 · Cited by 6
Masimirembwa, C. M., Ramsay, M., Botha, J. F., Ellis, E. C. S., Etheredge, H. R., Hurrell, T., Kanji, C. R., Kapungu, N. N., Maher, H., Mthembu, B., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001400 · Cited by 6
MacMahon, M., Hwang, W., Yim, S., MacMahon, E., Abraham, A., Barton, J., Tharmakulasingam, M., Bilokon, P., Gaddi, V. P., & Han, N. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101387 · Cited by 6
Deep generative models in the quest for anticancer drugs: ways forward
Romanelli, V., Cerchia, C., & Lavecchia, A. (2024) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2024.1362956 · Cited by 6
Priority index for critical Covid-19 identifies clinically actionable targets and drugs
Zhang, Z., Wang, S., Jiang, L., Wei, J., Lu, C., Li, S., Diao, Y., Fang, Z., He, S., Tan, T., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05897-0 · Cited by 6
In Silico Prediction of CNS Bioavailability
Talevi, A. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_4 · Cited by 6
Shyam, R., Singh, R., Bajpai, M., Palaniappan, A., & Parthasarathi, R. (2024) · Bioprinting · doi:10.1016/j.bprint.2024.e00363 · Cited by 6
Mathew, J., Zhou, B., Haney, R. S., Kunz, K. A., Amaral, L. S. D., Chowdhury, R. R., Butler, J. H., Li, H., Chakraborty, A. J., Tabassum, A., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00653 · Cited by 6
Jin, F., Hu, Q., Fei, H., Lv, H., Wang, S., Gui, B., Zhang, J., Tu, W., Zhang, Y., Zhang, L. J., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00443 · Cited by 6
Mushliha, Bustamam, A., Yanuar, A., Mangunwardoyo, W., Anki, P., & Amalia, R. (2021) · IEEE International Conference on Artificial Intelligence and Mechatronics Systems (AIMS) · doi:10.1109/aims52415.2021.9466040 · Cited by 6
Scott, J. A., Soto‐Velasquez, M., Hayes, M. P., LaVigne, J. E., Miller, H., Kaur, J. P., Ejendal, K. F. K., Watts, V. J., & Flaherty, D. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01759 · Cited by 6
Ganti, A., Yu, S., Sharpnack, D., Ingalla, E., & Bruyn, T. D. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2358 · Cited by 6
Godesi, S., Nada, H., Lee, J., Kang, J.-H., Kim, S., Choi, Y., & Lee, K. (2023) · Molecules · doi:10.3390/molecules28134952 · Cited by 6
Ayenero, M. E., Akinwusi, G. E., Kolawole, A. N., Falese, B. A., Olawuni, I. J., & Kolawole, A. O. (2023) · Journal of Molecular Recognition · doi:10.1002/jmr.3043 · Cited by 6
Naga, D., Dimitrakopoulou, S., Roberts, S., Husar, E., Mohr, S., Booler, H. S., & Musvasva, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-41899-4 · Cited by 6
Precision medicine: success stories and challenges from science to implementation
Seyhan, A. A., & Carini, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13963-5.00008-x · Cited by 6
Artificial Intelligence for Drug Toxicity and Safety
Joshi-Barr, S., & Wampole, M. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_134 · Cited by 6
Scoring of de novo Designed Chemical Entities by Macromolecular Target Prediction
Button, A. L., Hiss, J. A., Schneider, P., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201600110 · Cited by 6
Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors
Yousuf, M. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190320102238 · Cited by 6
How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development
Schäfer‐Korting, M., & Zoschke, C. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_374 · Cited by 6
Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2
Fischer, A., Sellner, M. S., Mitusińska, K., Bzówka, M., Lill, M. A., Góra, A., & Smieško, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042065 · Cited by 6
FRET-Based Probe for High-Throughput DNA Intercalator Drug Discovery and In Vivo Imaging
Murade, C. U., Chaudhuri, S., Nabti, I., Fahs, H. Z., Refai, F. S. M., Xie, X., Pearson, Y. E., Gunsalus, K. C., & Shubeita, G. T. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00167 · Cited by 6
Computational Methods in Multitarget Drug Discovery
Bottegoni, G., & Cavalli, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101011-2.00009-x · Cited by 6
Safety Assessment of Pharmaceuticals
Kenna, J. G., & Ram, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813697-3.00020-2 · Cited by 6
AI-driven Discovery of Morphomolecular Signatures in ToxicologyPreprint
Jaume, G., Peeters, T., Song, A. H., Pettit, R. W., Williamson, D. F. K., Oldenburg, L., Vaidya, A. J., de Brot, S., Chen, R. J., Thiran, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.19.604355 · Cited by 6
Ammara, A., Carone, A., Lucarini, L., Sgambellone, S., Marri, S., Villano, S., Matucci, R., Luga, G., Fittipaldi, C., Pecori, R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01459 · Cited by 5
Robert, K., Kaium, O., & Alasa, L. (2025) · International Journal of Multidisciplinary Evolutionary Research · doi:10.54660/ijmer.2025.6.2.44-52 · Cited by 5
Oral Mucosa‐on‐a‐Chip for Modeling Chemotherapy‐Induced Mucositis and Evaluating Drug Efficacy
Kim, Y. G., Lee, S., Oh, H., Choi, J., Jung, H., Kwak, B., & Kim, B. H. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202521887 · Cited by 5
Yu, S., Peng, Q., Wei, W., Li, X., & Long, S. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01296-2 · Cited by 5
Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules
Fernandes, G., Kim, S., dos Santos, J. L., Wang, Y., Soudy, C., Redmond, J. M., Castagnolo, D., & Todd, M. H. (2026) · Chemical Society Reviews · doi:10.1039/d5cs00617a · Cited by 5
Molecular Lead Optimization via Agentic Tool Planning
Li, L., Zhang, H., Fan, R., Chen, B., & Zhou, J. (2026) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/3770855.3819017 · Cited by 5
A two‐stage drop‐the‐losers design for time‐to‐event outcome using a historical control arm
Abbas, R., Wason, J. M. S., Michiels, S., & Teuff, G. L. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2168 · Cited by 5
Measuring the rapid kinetics of receptor-ligand interactions in live cells using NanoBRET
Suchankova, A., Harris, M., & Ladds, G. (2021) · Methods in cell biology · doi:10.1016/bs.mcb.2021.06.013 · Cited by 5
Tauheed, A. M., Mamman, M., Ahmed, A., Сулейман, М. М., & Balogun, E. O. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100223 · Cited by 5
Causative Role of Anoxic Environment in Bacterial Regulation of Human Intestinal Function
Wang, C., Cancino, A., Baste, J., Marten, D., Joshi, A. A., Nasreen, A., & Bhushan, A. (2022) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-022-00735-x · Cited by 5
Optimizing drug discovery: An opportunity and application with reverse translational research
Musyuni, P., Sharma, R., & Aggarwal, G. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100074 · Cited by 5
Bao, C., Gu, L., Wang, S., Zou, K., Zhang, Z., Jiang, L., Chen, L., & Fang, H. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107095 · Cited by 5
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Development
Dash, R., Munni, Y. A., Mitra, S., Dash, N., & Moon, I. S. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_15 · Cited by 5
Mansur, M. C. (2025) · European Journal of Artificial Intelligence and Machine Learning · doi:10.24018/ejai.2025.4.3.65 · Cited by 5
Quantifying the probability of pharmacological success to inform compound progression decisions
Zhou, X., Graff, O. X., & Chen, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240234 · Cited by 5
Schittny, A., Waldner, S., Duthaler, U., Vorobyev, A., Abramovich, R. A., Krähenbühl, S., Puchkov, M., & Huwyler, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030401 · Cited by 5
Marholz, L. J., Federspiel, J. D., Suh, H., & Ocaña, M. F. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00199 · Cited by 5
Lauffer, M. C. (2021) · Medizinische Genetik · doi:10.1515/medgen-2021-2085 · Cited by 5
Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs
Bieber, J. M., Sanman, L. E., Sun, X., Hammerlindl, H., Bao, F., Roth, M. A., Koleske, M. L., Huang, L., Aweeka, F., Wu, L. F., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03048-x · Cited by 5
Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models
Brigo, A., Naga, D., & Muster, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_24 · Cited by 5
Al‐Bari, M. A. A. (2022) · All Life · doi:10.1080/26895293.2022.2078894 · Cited by 5
Rakkhitawatthana, V., Sillapachaiyaporn, C., Nilkhet, S., Brimson, J. M., & Tencomnao, T. (2022) · Journal of Associated Medical Sciences · doi:10.12982/jams.2023.010 · Cited by 5
Old Drugs, New Indications (Review)
Мирошниченко, И. И., Valdman, E. A., & Kuz'min, I. I. (2023) · Drug development & registration · doi:10.33380/2305-2066-2023-12-1-182-190 · Cited by 5
In vitro-in silico pharmacology and chemistry of Stercularin, isolated from Sterculia diversifolia
Ahmad, I., Rabbi, F., Nisar, A., Ul‐Haq, Z., & Khan, A. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.108008 · Cited by 5
Drug repurposing for parasitic protozoan diseases
Vijayasurya, Gupta, S., Shah, S. K., & Pappachan, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.05.001 · Cited by 5
MOL-MOE: Learning Drug Molecular Characterization Based on Mixture of Expert Mechanism
Zhang, X., Qian, C., Xia, J., & Yang, F. (2024) · Lecture notes in computer science · doi:10.1007/978-981-97-5131-0_20 · Cited by 5
Schwarzinger, J., Adelsberger, S., Ortmayr, K., Stellnberger, S. L., Tahir, A., Hädrich, G., Pichler, V., Rollinger, J. M., Grienke, U., & Dailey, L. A. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100272 · Cited by 5
Silva-Rodrigues, G., de Castro, I. M., Borges, P. H. G., Suzukawa, H. T., de Souza, J. M., Bartolomeu-Gonçalves, G., Pelisson, M., Medeiros, C. I. S., Bispo, M. D. L. F., Almeida, R. S., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081053 · Cited by 5
When the drugs (don’t) work: The role of science in product commercialization
Anckaert, P. (2025) · Research Policy · doi:10.1016/j.respol.2025.105237 · Cited by 5
Bridging academic science and clinical research in the search for novel targeted anti-cancer agents.
Matter, A. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0079 · Cited by 5
Sjögren, E., Andersson, S. B. E., Sundgren‐Andersson, A. K., Halldin, M. M., & Stålberg, O. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.04.030 · Cited by 5
Xu, H., Song, Y., & Yang, Q. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-01010 · Cited by 5
Wang, C., & Chen, B. (2022) · Stresses · doi:10.3390/stresses2040029 · Cited by 5
Harishkumar, S., Nd, S., & Mahantheshappa, S. S. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i4.24147 · Cited by 5
Approaches to Solid‐Form Screening
Hilfiker, R., Blatter, F., Szelagiewicz, M., & von Raumer, M. (2018) · Wiley eBooks · doi:10.1002/9783527697847.ch8 · Cited by 5
Functional-genetic approaches to understanding drug response and resistance
Hinterndorfer, M., & Zuber, J. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.03.003 · Cited by 5
Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis
Ng, P. R., Belgur, C., Barthakur, S., van der Meer, A. D., Hamilton, G. A., & Barrile, R. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.08.004 · Cited by 5
Kinetics of ligand binding and signaling
Gherbi, K., Groenewoud, N. J., Holliday, N. D., Sengmany, K., & Charlton, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00010-6 · Cited by 5
Drug Screening Platforms and RPPA
Dawson, J. C., Warchal, S. J., & Carragher, N. O. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9755-5_11 · Cited by 5
Minocherhomji, S., Liu, Y., He, Y. D., & Fielden, M. R. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22364 · Cited by 5
Psychiatric Drug Discovery and Development
Shahid, M., Neill, J. C., & Hutchison, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.004 · Cited by 5
Synthesis and biological screening of a library of macamides as TNF-α inhibitors
Pérez, V. T., Ticona, L. A., Șerban, A. M., Gómez, J. A., & Sánchez, Á. R. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00208a · Cited by 5
Cotrina, E. Y., Blasi, D., Vilà, M., Planas, A., Abad‐Zapatero, C., Centeno, N. B., Quintana, J. R., & Arsequell, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115794 · Cited by 5
Evaluation of FOXO1 Target Engagement Using a Single-Cell Microfluidic Platform
Osman, S., Bendtsen, C., Peel, S. E., Yrlid, L., Muthas, D., Simpson, J., Willison, K. R., & Klug, D. R. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02808 · Cited by 5
Liang, J., Sohrabi, A., Epperson, M., Rad, L. M., Tamura, K., Sathialingam, M., Skandakumar, T., Lue, P., Huang, J. Y., Popoli, J., et al. (2022) · Journal of Visualized Experiments · doi:10.3791/63791 · Cited by 5
Hamimed, M., Leblond, P., Dumont, A., Gattacceca, F., Tresch‐Bruneel, E., Probst, A., Chastagner, P. B., Pagnier, A., Carli, É. D., Entz‐Werlé, N., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04446-y · Cited by 5
Kinetic Stability and Glass-Forming Ability of Thermally Labile Quinolone Antibiotics
Lapuk, S. E., Mukhametzyanov, T. A., Schick, C. H., & Gerasimov, A. V. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00211 · Cited by 5
Ferrero, E. (2018) · F1000Research · doi:10.12688/f1000research.13577.1 · Cited by 5
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.